Ligand Pharmaceuticals (LGND) Competitors $111.56 -0.24 (-0.21%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends LGND vs. NRIX, TVTX, PRAX, ARCT, CMPS, RGEN, MDGL, HALO, IONS, and ALKSShould you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Nurix Therapeutics (NRIX), Travere Therapeutics (TVTX), Praxis Precision Medicines (PRAX), Arcturus Therapeutics (ARCT), COMPASS Pathways (CMPS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), and Alkermes (ALKS). These companies are all part of the "medical" sector. Ligand Pharmaceuticals vs. Nurix Therapeutics Travere Therapeutics Praxis Precision Medicines Arcturus Therapeutics COMPASS Pathways Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Ligand Pharmaceuticals (NASDAQ:LGND) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability. Is LGND or NRIX more profitable? Ligand Pharmaceuticals has a net margin of 29.68% compared to Nurix Therapeutics' net margin of -313.65%. Ligand Pharmaceuticals' return on equity of 4.95% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals29.68% 4.95% 4.39% Nurix Therapeutics -313.65%-63.39%-41.82% Do analysts rate LGND or NRIX? Ligand Pharmaceuticals currently has a consensus price target of $144.83, suggesting a potential upside of 29.83%. Nurix Therapeutics has a consensus price target of $29.40, suggesting a potential upside of 29.86%. Given Nurix Therapeutics' higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Nurix Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has more volatility and risk, LGND or NRIX? Ligand Pharmaceuticals has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Does the media refer more to LGND or NRIX? In the previous week, Nurix Therapeutics had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 5 mentions for Nurix Therapeutics and 2 mentions for Ligand Pharmaceuticals. Nurix Therapeutics' average media sentiment score of 0.91 beat Ligand Pharmaceuticals' score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, LGND or NRIX? Ligand Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$152.42M13.83$52.15M$2.5144.45Nurix Therapeutics$76.99M20.83-$143.95M-$2.91-7.78 Do insiders & institutionals have more ownership in LGND or NRIX? 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 5.9% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 9.8% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer LGND or NRIX? Ligand Pharmaceuticals received 477 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 78.02% of users gave Nurix Therapeutics an outperform vote while only 70.62% of users gave Ligand Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLigand PharmaceuticalsOutperform Votes54870.62% Underperform Votes22829.38% Nurix TherapeuticsOutperform Votes7178.02% Underperform Votes2021.98% SummaryLigand Pharmaceuticals beats Nurix Therapeutics on 10 of the 18 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGND vs. The Competition Export to ExcelMetricLigand PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.11B$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio44.4510.78135.4117.82Price / Sales13.83243.751,160.9774.56Price / Cash22.3322.1633.5332.53Price / Book2.765.474.674.68Net Income$52.15M$153.61M$119.07M$226.08M7 Day Performance-3.37%-2.00%-1.83%-1.04%1 Month Performance4.48%-7.46%-3.60%1.04%1 Year Performance90.77%31.82%31.66%26.28% Ligand Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGNDLigand Pharmaceuticals4.9545 of 5 stars$111.56-0.2%$144.83+29.8%+91.9%$2.11B$131.31M44.4580NRIXNurix Therapeutics2.7301 of 5 stars$22.64-0.7%$29.40+29.9%+247.8%$1.61B$76.99M0.00300TVTXTravere Therapeutics3.0581 of 5 stars$17.86+2.7%$22.62+26.6%+210.6%$1.36B$145.24M0.00460PRAXPraxis Precision Medicines1.7647 of 5 stars$73.68+1.3%$146.33+98.6%+299.3%$1.36B$2.45M0.00110ARCTArcturus Therapeutics2.0511 of 5 stars$16.17-10.5%$71.40+341.6%-33.7%$489.20M$169.93M-7.28180CMPSCOMPASS Pathways2.8433 of 5 stars$4.66-2.1%$30.67+558.1%-23.0%$325.68MN/A0.00120Short Interest ↓RGENRepligen4.6331 of 5 stars$138.90+8.1%$190.25+37.0%-10.8%$7.20B$638.76M0.001,783Positive NewsMDGLMadrigal Pharmaceuticals3.7989 of 5 stars$317.09+0.9%$347.33+9.5%+66.8%$6.85BN/A-12.6490Analyst ForecastHALOHalozyme Therapeutics4.9812 of 5 stars$45.76+2.1%$61.11+33.5%+14.4%$5.70B$829.25M15.15390Analyst ForecastIONSIonis Pharmaceuticals4.2197 of 5 stars$35.40+4.9%$60.65+71.3%-28.7%$5.33B$788M0.00800ALKSAlkermes4.7847 of 5 stars$27.91+1.6%$35.42+26.9%+15.4%$4.45B$1.66B14.312,100Positive News Related Companies and Tools Related Companies NRIX Competitors TVTX Competitors PRAX Competitors ARCT Competitors CMPS Competitors RGEN Competitors MDGL Competitors HALO Competitors IONS Competitors ALKS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LGND) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LGND Stock Alerts